Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Van Assche G, et al. Among authors: vexler v. Gut. 2006 Nov;55(11):1568-74. doi: 10.1136/gut.2005.089854. Epub 2006 Apr 7. Gut. 2006. PMID: 16603634 Free PMC article. Clinical Trial.
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS. Sheridan JP, et al. Among authors: vexler v. Mult Scler. 2011 Dec;17(12):1441-8. doi: 10.1177/1352458511414755. Epub 2011 Aug 1. Mult Scler. 2011. PMID: 21807759 Clinical Trial.
The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
Ganguly B, Balasa B, Efros L, Hinton PR, Hartman S, Thakur A, Xiong JM, Schmidt B, Robinson RR, Sornasse T, Vexler V, Sheridan JP. Ganguly B, et al. Among authors: vexler v. MAbs. 2016 Oct;8(7):1417-1424. doi: 10.1080/19420862.2016.1207031. Epub 2016 Jul 1. MAbs. 2016. PMID: 27367933 Free PMC article.
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. Hsi ED, et al. Among authors: vexler v. Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246. Clin Cancer Res. 2008. PMID: 18451245 Free PMC article.
41 results